Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published September 12th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.

View original document View source feed page

What changed

This document is a publication of a patent application (US20260085067A1) filed with the USPTO. It describes compounds and methods for treating cancer using cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors. The application was filed on September 12, 2023, and lists Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong as inventors.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property developments in cancer therapeutics. Companies involved in drug discovery and development, particularly in oncology, should be aware of this filing for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

Application US20260085067A1 Kind: A1 Mar 26, 2026

Inventors

Anthony B. PINKERTON, Jacques MAUGER, Yen Pham Hong TRUONG

Abstract

Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.